Skip to content
The Policy VaultThe Policy Vault

ZytigaMedica

Prostate cancer – regional risk group

Initial criteria

  • age ≥ 18 years
  • used in combination with prednisone
  • regional lymph node metastases and no distant metastases
  • ONE of the following: concurrently used with a gonadotropin-releasing hormone (GnRH) analog OR patient has had a bilateral orchiectomy

Approval duration

1 year